4D Molecular Therapeutics FDMT Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's current ratio?
- 4D Molecular Therapeutics (FDMT) reported current ratio of 9.3× in Q1 2026.
- How has 4D Molecular Therapeutics's current ratio changed year-over-year?
- 4D Molecular Therapeutics's current ratio decreased by 24.5% year-over-year, from 12.4× to 9.3×.
- What is the long-term trend for 4D Molecular Therapeutics's current ratio?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's current ratio has grown at a -11.1% compound annual growth rate (CAGR), from 16.9× to 9.4×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.